FY2025 · ended Dec 31, 2025 · Revenue $45.15M, +53.4% YoY · Filed Mar 5, 2026
TriSalus Life Sciences, Inc. (TLSI) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $45.2 million and a net loss of $39.2 million. Free cash flow was -$18.9 million. As of Jun 30, 2026 it held $46.3 million in cash and investments and $33.1 million in total debt.
Revenue (TTM)
$45.08M
+25.2% vs year-ago TTM
Net income (TTM)
$-28.21M
+9.5% vs year-ago TTM
Operating cash flow (TTM)
$-22.80M
+19.6% vs year-ago TTM
Free cash flow (TTM)
$-23.28M
+20.4% vs year-ago TTM
EPS (TTM)
$-1.15
+3.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
61.31M
+90.0% vs prior year
Net cash
$13.22M
as of Jun 30, 2026
Operating margin
-67.7%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TLSI (Nasdaq), TLSIW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westminster, CO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1826667
- Former names
- MedTech Acquisition Corp (until Aug 10, 2023); MedTech Acquisition Corporation (until Oct 29, 2020)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $45.2M | $29.4M | $18.5M | — | — |
| Operating income | -$26.9M | -$36.2M | -$54.5M | -$36.4M | -$3.0M |
| Net income | -$39.2M | -$30.0M | -$59.4M | -$47.2M | $4.8M |
| Diluted EPS | -$1.84 | -$1.31 | -$6.77 | — | — |
| Operating cash flow | -$18.0M | -$40.8M | -$50.6M | -$32.3M | -$1.7M |
| Free cash flow | -$18.9M | -$41.2M | -$51.2M | — | — |
| Total assets | $35.3M | $24.0M | $24.6M | $22.0M | $250.5M |
| Total liabilities | $69.2M | $49.9M | $51.7M | $34.3M | $17.3M |
| Stockholders' equity | -$33.9M | -$25.9M | -$27.1M | -$177.1M | -$129.6M |
| Cash and investments | $20.4M | $8.5M | $11.8M | $9.4M | $200,884 |
| Total debt | $34.4M | $23.6M | $1.6M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Sep 22, 2026 | Sep 22, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 493 TriSalus Life Sciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.